Hikma Pharmaceuticals Public annual gross margin
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Gross Margin Growth & History (HIK)
Hikma Pharmaceuticals Public's gross margin was 43.03% for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 43.03% | −2.22 pp |
| 2024 | 2024-12-31 | 45.25% | −3.10 pp |
| 2023 | 2023-12-31 | 48.35% | −0.84 pp |
| 2022 | 2022-12-31 | 49.19% | −1.77 pp |
| 2021 | 2021-12-31 | 50.96% | −0.34 pp |
| 2020 | 2020-12-31 | 51.30% | — |
Hikma Pharmaceuticals Public gross margin trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's gross margin decreased from 51.30% to 43.03%, a change of −8.28 percentage points.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as reported gross profit divided by reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...